OPHLY.US Ono Pharmaceutical Co Ltd
- Market cap
- USD 7.28B
- P/E
- 15.2x
- P/B
- 1.33x
- ROE
- 10.3%
- Dividend yield
- 3.26%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is OPHLY.US undervalued?
Graham numberOPHLY.US trades 5.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ono Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Ono Pharmaceutical Co Ltd yet.
Ono Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ono Pharmaceutical Co Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also p…
Full company profileOno Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ono Pharmaceutical Co Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 245B | 262B | 289B | 292B | 309B | 361B | 447B | 503B | 487B | 547B | 468B |
| Gross Profit | 179B | 196B | 205B | 213B | 224B | 268B | 337B | 376B | 339B | 397B | 352B |
| Operating Income | 72.3B | 60.7B | 62.0B | 77.5B | 98.3B | 103B | 142B | 163B | 59.7B | 110B | 117B |
| EBITDA | 83.9B | 67.4B | 74.2B | 94.8B | 117B | 124B | 162B | 178B | 91.5B | 150B | 153B |
| Net Income | 55.8B | 50.3B | 51.5B | 59.7B | 75.4B | 80.5B | 113B | 128B | 50.0B | 74.0B | 90.5B |
| EPS | 12 | 11 | 11 | 13 | 17 | 18 | 26 | 89 | 36 | 52 | 64 |
| Balance Sheet | |||||||||||
| Total Assets | 617B | 609B | 655B | 673B | 747B | 739B | 882B | 914B | 1.06T | 1.11T | 1.10T |
| Total Liabilities | 93.3B | 79.6B | 92.3B | 105B | 106B | 77.5B | 135B | 115B | 276B | 251B | 211B |
| Shareholders' Equity | 519B | 524B | 557B | 562B | 636B | 656B | 742B | 793B | 782B | 854B | 881B |
| Cash & Short-term Investments | 165B | 85.8B | 71.5B | 100B | 105B | 117B | 164B | 205B | 210B | 238B | 260B |
| Total Debt | 965M | 712M | 2.20B | 8.36B | 9.05B | 8.80B | 9.17B | 8.86B | 147B | 121B | 111B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 74.5B | 15.7B | 66.8B | 74.2B | 74.0B | 61.8B | 160B | 111B | 82.5B | 145B | 100B |
| Capital Expenditure | 24.1B | 29.8B | 29.6B | 22.4B | 20.3B | 12.3B | 14.5B | 20.8B | 7.99B | 6.39B | 6.55B |
| Free Cash Flow | 50.4B | -14.1B | 37.2B | 51.7B | 53.7B | 49.6B | 145B | 89.8B | 74.5B | 139B | 93.8B |
| Ratios | |||||||||||
| ROE | 10.7% | 9.6% | 9.2% | 10.6% | 11.9% | 12.3% | 15.2% | 16.1% | 6.4% | 8.7% | 10.3% |
| ROA | 9.0% | 8.3% | 7.9% | 8.9% | 10.1% | 10.9% | 12.8% | 14.0% | 4.7% | 6.7% | 8.2% |
| Net Profit Margin | 22.8% | 19.2% | 17.9% | 20.4% | 24.4% | 22.3% | 25.2% | 25.5% | 10.3% | 13.5% | 19.3% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.19x | 0.14x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ono Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.26%
- Forward dividend
- 0.17 USD
- Payout ratio
- 53.8%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 39.8B | 28 | 53.8% |
| 2025 | JPY 37.5B | 27 | 75.0% |
| 2024 | JPY 37.2B | 26 | 29.1% |
| 2023 | JPY 29.7B | 6.77 | 26.4% |
| 2022 | JPY 27.7B | 6.19 | 34.4% |
| 2021 | JPY 22.4B | 5.00 | 29.8% |
| 2020 | JPY 22.8B | 5.02 | 38.1% |
| 2019 | JPY 21.8B | 4.72 | 42.4% |
| 2018 | JPY 23.4B | 5.02 | 46.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Apr 4, 2016.
Who owns Ono Pharmaceutical Co Ltd
- Insiders 0.00%
- Institutions 0.01%
- Public & others 99.99%
- Shares outstanding 1.41B
- Free float 1.36B
Ono Pharmaceutical Co Ltd company profile
- Company name
- Ono Pharmaceutical Co Ltd
- Ticker
- OPHLY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,206
- Fiscal year end
- March
- Address
- 8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564
- Phone
- 81 6 6263 5670
- Website
- ono-pharma.com
About Ono Pharmaceutical Co Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has strategic collaboration with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; Congruence Therapeutics; and Aitia, Inc. for drug discovery of novel therapeutic targets for neurological diseases. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Ono Pharmaceutical Co Ltd management
10- Mr. Gyo SagaraCEO & Chairman of the Board · born 1958
- Mr. Toichi Takino Ph.D.President, COO & Representative Director · born 1968
- Mr. Toshihiro TsujinakaCorp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir · born 1964
- Mr. Masaki ItoCorporate Executive Officer, Chief Officer of Fin. & Accounting div.
- Takehiro YamadaCorporate Officer & VP of Compliance Promotion Department
- Ryuta ImuraVice President of Corporate Communications
- Hirokazu KitadaExecutive VP of Sales & Marketing and Corporate Officer
- Hiromu Habashita Ph.D.Corporate Officer, Senior Vice President, Discovery & Research
- Shinji Takai M.D., Ph.D.Corporate Officer & Executive Vice President of Medical Affairs
- Akira TakadaCorporate Executive Officer & Executive Director of CMC & Production